You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》安進藥廠(AMGN.US)季度收入勝預期 宣布收購ChemoCentryx(CCXI.US)
道指成分股,美國安進藥廠(Amgen)(AMGN.US)公布第二季度業績。季度淨利潤13.17億美元,按升1.84倍,每股季度攤薄純利2.45美元,經調整後為4.65美元。季度總收入65.94億美元,按年升1%,市場預期為65.3億美元。 期內關節炎藥Enbrel銷售按年跌8%至10.5億美元,骨質疏鬆症藥物Prolia銷售按年升13%至9.22億美元。公司維持全年經調整每股純利介乎17至18美元。 公司亦宣布收購ChemoCentryx(CCXI.US),後者開發免疫性疾病藥物。收購作價每股52美元,為該股周三(3日)收市價1.16倍溢價,給予後者估值37億美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account